Rhinomed has a platform medical device technology that is protected globally by a family of over 60 patents and 57 design patents. Our nasal platform envisages multiple applications from simple stenting through to nasal drug delivery and sensor/diagnostics.
Our R&D programs seek to understand how the platform can be adapted to solve specific unmet clinical needs in the following markets:
The impact of sleep and respiratory
function on cognitive issues
Obstructive sleep apnea
Diagnostics and sensors
The nose is a well recognised site for the delivery of medication and the Rhinomed proprietary drug delivery platform is capable of delivering medication into the nose in an inhaled form or via a trans-dermal or trans-mucosal method.
Many of the challenges related to exiting nasal drug delivery solutions such as loss at the back of the throat, complexity surrounding spray areas, and accuracy of dosing levels can be resolved by the Rhinomed platform.
Rhinomed’s in-situ delivery system ensures a specific level of API can be delivered in a controlled manner at a specific site.
Rhinomed has licensed its technology as a drug delivery platform in the US market for the delivery of cannabinoids to one of North America’s leading medical cannabis companies – Columbia Care (CCHW:NE). This agreement will enable Columbia Care to nasally deliver a range of cannabinoid formulations that target several significant markets.
We are always interested in working with innovative organisations and individuals who believe they can make a real difference.
Please CONTACT US to discuss how we might collaborate.